How are rare blood disorders treated?
Treatment for rare blood disorders depends on the type and extent of disease.
Treatment for histiocytosis could involve:
- Chemotherapy. This is medicine that targets the abnormal blood cells.
- Radiation therapy. Your doctor may prescribe low-dose radiation therapy to treat bone or skin tumors.
- Surgery. Traditional surgery can remove bone and skin tumors.
Treatment for PNH could involve:
- Bone marrow transplant. This procedure injects healthy blood-forming cells into your bloodstream. You must be a good candidate.
- Immunotherapy. These medicines stimulate an immune response that targets abnormal blood cells.
- Blood transfusions. Healthy red blood cells can be injected into your bloodstream to treat anemia caused by PNH.
- Dietary supplements. In some cases, your doctor could prescribe folic acid or iron to treat anemia caused by PNH.
- Medicines. Anticoagulants or plasminogen activators can treat blood clots caused by PNH.
Learn the treatment options for myeloproliferative diseases.
A multidisciplinary team of cancer experts including surgeons, medical oncologists, radiation oncologists, plastic reconstructive surgeons, pathologists, radiologists, genetic counselors, medical geneticists, social workers, patient navigators and clinical trials staff meet weekly to discuss select complex cases and determine the best course of care. Stem cell transplantation experts and hematologic oncology experts are also available to discuss complex cases.
Miami Cancer Institute can provide access to clinical trials not widely available elsewhere. Clinical trials find new ways to treat and diagnose cancer and are ongoing. If an appropriate trial is available, we will talk to you about the benefits and risks.
Patient Support Services
Taking care of the whole patient is an important component of providing personalized cancer care. Integrated into the fabric of the Miami Cancer Institute, the Cancer Patient Support Center addresses the psychological, physical, social and spiritual needs of our patients during cancer treatment and beyond.